By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept

Our Pipeline

Our allogeneic, virus-specific T cell (VST) therapy candidates target 11 different devastating viruses as treatment or prevention.
Learn more

Our Platform

Our proprietary platform develops off-the-shelf VSTs that restore immunity in patients with T cell deficiencies.
Learn more
a hand in purple gloves handling medicine
a woman and two men sitting in a meeting room discussing

Our People

We have a singular vision: to create T cell therapies that serve patients at risk of the devastating consequences of severe viral diseases.
Meet the team

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno